Pharmacogenetic Trial of a Cannabinoid Agonist Shows Reduced Fasting Colonic Motility in Patients With Nonconstipated Irritable Bowel Syndrome

Article ID	Journal	Published Year	Pages	File Type
6095659	Gastroenterology	2011	17 Pages	PDF

Abstract

In patients with IBS with diarrhea or alternating, dronabinol reduces fasting colonic motility; FAAH and CNR1 variants could influence the effects of this drug on colonic motility.

Keywords

VAS FAAH IBS-C IBS-D IBS-A mgll Fatty acid amide hydrolase Sensory irritable bowel syndrome with diarrhea irritable bowel syndrome with constipation motility index monoacylglycerol lipase Drug metabolism visual analogue scale motor Clinical trial

Related Topics

Health Sciences Medicine and Dentistry Gastroenterology

Preview

Pharmacogenetic Trial of a Cannabinoid Agonist Shows Reduced Fasting Colonic Motility in Patients With Nonconstipated Irritable Bowel Syndrome

Authors

Banny S. Wong, Michael Camilleri, Irene Busciglio, Paula Carlson, Lawrence A. Szarka, Duane Burton, Alan R. Zinsmeister,